| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine, Pathology and the Molecular Biology Program, University of Colorado Health Sciences Center, Aurora, Colorado 80045
Address all correspondence and requests for reprints to: Britta M. Jacobsen, Ph.D., Department of Medicine/Endocrinology, University of Colorado School of Medicine, Mail Stop 8106, PO Box 6511, Aurora, Colorado 80045. E-mail: Britta.Jacobsen{at}uchsc.edu.
Progesterone receptors (PRs) are prognostic markers in breast cancers irrespective of the patient’s progestational status. However, there are two PR isoforms, PR-A and PR-B, that are equimolar in the normal breast but dysregulated in advanced disease. Postmenopausal, tamoxifen-treated patients with estrogen receptor (ER)-positive, PR-A-rich tumors have much faster disease recurrence than patients with PR-B-rich tumors. To study the mechanisms we engineered ER+ breast cancer cells that express each PR isoform under control of an inducible promoter. We identified 79 genes regulated by progesterone (P), mainly by PR-B, and 51 genes regulated without progesterone, mainly by PR-A. Only nine genes were regulated with and without ligand, leading to definition of three classes: I) genes regulated only by liganded PR; II) genes regulated only by unliganded PR; III) genes regulated by both. Unliganded PR-A and PR-B differentially regulate genes that coordinate extracellular signaling pathways and influence tumor cell biology. Indeed, in the absence of P, compared with ER+/PR-B+ or PR– cells, ER+, PR-A+ cells exhibit an aggressive phenotype, are more adhesive to an extracellular matrix, and are more migratory. Additionally, unliganded PR-A and PR-B both inhibit cell growth and provoke resistance to Taxol-induced apoptosis. We propose that PR-A:PR-B ratios, even in the absence of P, influence the biology and treatment response of ER+ tumors, that PR-A isoforms are functionally dominant in P-deficient states, and that PR-A rich tumors are especially aggressive.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  E. C. Ward, A. V. Hoekstra, L. J. Blok, P. Hanifi-Moghaddam, J. R. Lurain, D. K. Singh, B. M. Buttin, J. C. Schink, and J. J. Kim The Regulation and Function of the Forkhead Transcription Factor, Forkhead Box O1, Is Dependent on the Progesterone Receptor in Endometrial Carcinoma Endocrinology, April 1, 2008; 149(4): 1942 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bukulmez, D. B. Hardy, B. R. Carr, R. A. Word, and C. R. Mendelson Inflammatory Status Influences Aromatase and Steroid Receptor Expression in Endometriosis Endocrinology, March 1, 2008; 149(3): 1190 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Daniel, E. J. Faivre, and C. A. Lange Phosphorylation-Dependent Antagonism of Sumoylation Derepresses Progesterone Receptor Action in Breast Cancer Cells Mol. Endocrinol., December 1, 2007; 21(12): 2890 - 2906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takano, Z. Lu, T. Goto, L. Fusi, J. Higham, J. Francis, A. Withey, J. Hardt, B. Cloke, A. V. Stavropoulou, et al. Transcriptional Cross Talk between the Forkhead Transcription Factor Forkhead Box O1A and the Progesterone Receptor Coordinates Cell Cycle Regulation and Differentiation in Human Endometrial Stromal Cells Mol. Endocrinol., October 1, 2007; 21(10): 2334 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Carnevale, C. J. Proietti, M. Salatino, A. Urtreger, G. Peluffo, D. P. Edwards, V. Boonyaratanakornkit, E. H. Charreau, E. B. de Kier Joffe, R. Schillaci, et al. Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways Mol. Endocrinol., June 1, 2007; 21(6): 1335 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kariagina, M. D. Aupperlee, and S. Z. Haslam Progesterone Receptor Isoforms and Proliferation in the Rat Mammary Gland during Development Endocrinology, June 1, 2007; 148(6): 2723 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Arnett-Mansfield, J. D. Graham, A. R. Hanson, P. A. Mote, A. Gompel, L. L. Scurr, N. Gava, A. de Fazio, and C. L. Clarke Focal Subnuclear Distribution of Progesterone Receptor Is Ligand Dependent and Associated with Transcriptional Activity Mol. Endocrinol., January 1, 2007; 21(1): 14 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Brayman, J. Julian, B. Mulac-Jericevic, O. M. Conneely, D. P. Edwards, and D. D. Carson Progesterone Receptor Isoforms A and B Differentially Regulate MUC1 Expression in Uterine Epithelial Cells Mol. Endocrinol., October 1, 2006; 20(10): 2278 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Graham, M. L. Yager, H. D. Hill, K. Byth, G. M. O'Neill, and C. L. Clarke Altered Progesterone Receptor Isoform Expression Remodels Progestin Responsiveness of Breast Cancer Cells Mol. Endocrinol., November 1, 2005; 19(11): 2713 - 2735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Aupperlee, K. T. Smith, A. Kariagina, and S. Z. Haslam Progesterone Receptor Isoforms A and B: Temporal and Spatial Differences in Expression during Murine Mammary Gland Development Endocrinology, August 1, 2005; 146(8): 3577 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chwalisz, M. C. Perez, D. DeManno, C. Winkel, G. Schubert, and W. Elger Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis Endocr. Rev., May 1, 2005; 26(3): 423 - 438. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
